Prognostic factors and outcome analysis of salivary duct carcinoma

被引:27
作者
Han, Myung Woul [1 ]
Roh, Jong-Lyel [2 ]
Choi, Seung-Ho [2 ]
Nam, Soon Yuhl [2 ]
Lee, Hee Jin [3 ]
Cho, Kyung-Ja [3 ]
Lee, Sang-Wook [4 ]
Kim, Sang Yoon [2 ,5 ]
机构
[1] Ulsan Univ Hosp, Dept Otolaryngol, Ulsan, South Korea
[2] Univ Ulsan, Coll Med, Dept Otolaryngol, Asan Med Ctr, Seoul, South Korea
[3] Univ Ulsan, Coll Med, Dept Pathol, Asan Med Ctr, Seoul, South Korea
[4] Univ Ulsan, Coll Med, Dept Radiat Oncol, Asan Med Ctr, Seoul, South Korea
[5] Korea Inst Sci & Technol, Biomed Res Inst, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
Salivary duct carcinoma; Radiotherapy; Distant metastasis; c-erbB-2; EGFR; GLAND CARCINOMAS; BREAST-CANCER; PAROTID-GLAND; PHASE-II; TRASTUZUMAB; EXPRESSION; THERAPY; CHEMORADIOTHERAPY; OVEREXPRESSION; MALIGNANCIES;
D O I
10.1016/j.anl.2015.04.005
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Objective: Salivary duct carcinoma (SDC) is highly aggressive, with high rates of recurrence and nodal and distant metastases. The aim of the current study was to evaluate the clinical implication of EGFR and HER2 expression for predicting prognosis and to identify the factors associated with outcome. Methods: The medical records of 28 patients with SDC underwent surgery and adjuvant RT. Expression of c-erbB-2 and EGFR was determined immunohistochemically on the 25 SDC specimens. Disease-free survival (DFS), overall survival (OS) and distant metastasis-free survival (DMFS) were analyzed. Results: Three-year DFS, OS and DMFS rates were 38.3%, 78.1% and 45.7%, respectively. Expression of c-erbB-2 and EGFR was seen in 64% and 40%. c-erbB-2 and EGFR expression did not correlate with recurrence or metastasis. Advanced N classification and perineural invasion (PNI) were significant predictors of DFS and DMFS. Conclusion: c-erbB-2 and EGFR expression did not correlate with recurrence or metastasis. Despite aggressive surgery and RT, approximately 50% of SDCs failed systemically. More effective therapy to inhibit distant metastases in patients with advanced N classification and PNI should be considered. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:472 / 477
页数:6
相关论文
共 34 条
[1]   Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non-adenoid cystic carcinoma malignant tumors of the salivary glands [J].
Agulnik, Mark ;
Cohen, Ezra W. E. ;
Cohen, Roger B. ;
Chen, Eric X. ;
Vokes, Everett E. ;
Hotte, Sebastien J. ;
Winquist, Eric ;
Laurie, Scott ;
Hayes, D. Neil ;
Dancey, Janet E. ;
Brown, Shirley ;
Pond, Gregory R. ;
Lorimer, Ian ;
Daneshmand, Manijeh ;
Ho, James ;
Tsao, Ming-Sound ;
Siu, Lillian L. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (25) :3978-3984
[2]   Emerging Targeted Therapies for Breast Cancerd [J].
Alvarez, Ricardo H. ;
Valero, Vicente ;
Hortobagyi, Gabriel N. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (20) :3366-3379
[3]   SALIVARY DUCT CARCINOMA .2. IMMUNOHISTOCHEMICAL EVALUATION OF 13 CASES FOR ESTROGEN AND PROGESTERONE RECEPTORS, CATHEPSIN-D, AND C-ERB-2 PROTEIN [J].
BARNES, L ;
RAO, U ;
CONTIS, L ;
KRAUSE, J ;
SCHWARTZ, A ;
SCALAMOGNA, P .
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTOLOGY, 1994, 78 (01) :74-80
[4]   Treatment of HER2-overexpressing breast cancer [J].
Baselga, J. .
ANNALS OF ONCOLOGY, 2010, 21 :36-40
[5]   Salivary gland cancers: current treatments, molecular characteristics and new therapies [J].
Chandana, Sreenivasa R. ;
Conley, Barbara A. .
EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (04) :645-652
[6]   Human epidermal growth factor receptor 2 (HER2) in salivary gland carcinomas [J].
Clauditz, Till Sebastian ;
Reiff, Maren ;
Gravert, Linn ;
Gnoss, Alexander ;
Tsourlakis, Maria-Christina ;
Muenscher, Adrian ;
Sauter, Guido ;
Bokemeyer, Carsten ;
Knecht, Rainald ;
Wilczak, Waldemar .
PATHOLOGY, 2011, 43 (05) :459-464
[7]   Amplification and overexpression of HER2/neu gene and HER2/neu protein in salivary duct carcinoma of the parotid gland [J].
Cornolti, Giorgio ;
Ungari, Marco ;
Morassi, Maria Laura ;
Facchetti, Fabio ;
Rossi, Elisa ;
Lombardi, Davide ;
Nicolai, Piero .
ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2007, 133 (10) :1031-1036
[8]  
DELGADO R, 1993, CANCER, V72, P1503, DOI 10.1002/1097-0142(19930901)72:5<1503::AID-CNCR2820720503>3.0.CO
[9]  
2-K
[10]   Molecular predictors of response to trastuzumab and lapatinib in breast cancer [J].
Esteva, Francisco J. ;
Yu, Dihua ;
Hung, Mien-Chie ;
Hortobagyi, Gabriel N. .
NATURE REVIEWS CLINICAL ONCOLOGY, 2010, 7 (02) :98-107